Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Adobe Systems Inc. (NASDAQ: ADBE) shares spiked 5.58 percent to close at $45.78 a share Wednesday. The stock traded between $45.35 and $46.44 on volume of 12.57 million shares traded. The company reported revenues totaled $1.011 billion for the second quarter of fiscal 2013, which was within its guidance of $975 million to $1.025 billion Shares of Adobe Systems have gained approximately 21.5 percent year-to-date.
Get more information on Adobe Systems and free access to the in-depth equity report at: www.FiveStarEquities.com/ADBE
Biodel Inc. (NASDAQ: BIOD) shares declined 8.61 percent to close at $4.35 a share Wednesday. The stock traded between $4.21 and $4.62 on volume of 3.17 million shares traded. The company announced the pricing of a public offering of 4,482,760 shares of its common stock at $4.35 per share. Shares of Biodel have gained approximately 103.4 percent year-to-date.
Get more information on Biodel and free access to the in-depth equity report at: www.FiveStarEquities.com/BIOD
DISH Network Corp. (NASDAQ: DISH) shares gained 0.46 percent to close at $39.27 a share Wednesday. The stock traded between $38.92 and $40.71 on volume of 2.97 million shares traded. The company has announced that it would not submit a new offer to acquire Sprint Nextel Corp. by Tuesday’s deadline and would focus its attention on its tender offer for Clearwire Corp. Shares of DISH Network have gained approximately 7.9 percent year-to-date.
Get more information on DISH Network and free access to the in-depth equity report at: www.FiveStarEquities.com/DISH
Keryx Biopharmaceuticals (NASDAQ: KERX) shares spiked 7.57 percent to close at $8.24 a share Wednesday. The stock traded between $8.02 and $8.50 on volume of 9.27 million shares traded. J.P. Morgan has recently initiated coverage on the company with an “overweight” rating and a price target of $13.00. Shares of Keryx Biopharmaceuticals have gained approximately 214.5 percent year-to-date.
Get more information on Keryx Biopharmaceuticals and free access to the in-depth equity report at: www.FiveStarEquities.com/KERX
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:Five Star Equities [email protected]